These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31883008)

  • 1. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.
    Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Wood WA; Olszewski A; Basch E; Keating NL
    J Natl Cancer Inst; 2020 Oct; 112(10):1055-1062. PubMed ID: 31883008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
    Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
    J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.
    Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Basch E; Keating NL
    JAMA Health Forum; 2021 May; 2(5):e210673. PubMed ID: 35977314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Shen C; Zhao B; Liu L; Shih YT
    Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
    Cole AL; Jazowski SA; Dusetzina SB
    Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Chin AL; Bentley JP; Pollom EL
    Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
    Jazowski SA; Wilson L; Dusetzina SB; Zafar SY; Zullig LL
    JAMA Netw Open; 2022 Jun; 5(6):e2215720. PubMed ID: 35671056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Out-of-Pocket Spending and Premium Contributions After Implementation of the Affordable Care Act.
    Goldman AL; Woolhandler S; Himmelstein DU; Bor DH; McCormick D
    JAMA Intern Med; 2018 Mar; 178(3):347-355. PubMed ID: 29356828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the Mental Health Parity and Addiction Equity Act on Specialty Outpatient Behavioral Health Spending and Utilization.
    Gertner AK; Rotter J; Cruden G
    J Ment Health Policy Econ; 2018 Sep; 21(3):91-103. PubMed ID: 30530870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of parity on expenditures for individuals with severe mental illness.
    McConnell KJ
    Health Serv Res; 2013 Oct; 48(5):1634-52. PubMed ID: 23557191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
    Kenzik KM; Bhatia R; Bhatia S
    JAMA Oncol; 2020 Apr; 6(4):542-546. PubMed ID: 31999305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia.
    Darkow T; Maclean R; Joyce GF; Goldman D; Lakdawalla DN
    Am J Manag Care; 2012 Nov; 18(11 Suppl):S272-8. PubMed ID: 23327459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
    Jiang Q; Wang H; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.
    Yeager KA; Waldrop-Valverde D; Paul S; Bruner DW; Klisovic R; Burns E; Mason TA; Patel N; Jennings BM
    Res Nurs Health; 2020 Sep; 43(5):443-452. PubMed ID: 32866350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    Winn AN; Keating NL; Dusetzina SB
    J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
    Lam MS; Cheung N
    J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.